JSA advised Advent International and Suven Pharmaceuticals Limited, which is listed in India, in the ~USD 3 billion dollar (combined) merger of Cohance Lifesciences Limited with and into Suven Pharmaceuticals Limited, as one of the largest transactions of its kind.
Following the merger, Suven Pharmaceuticals Limited has now been renamed as Cohance Lifesciences Limited.
Our transaction team was led by Partner & National Corporate Lead, Iqbal Khan & Partner, Ambarish with support from Principal Associate, Krishaal Morjaria, Senior Associate, Tarini Sardesai & Associates Ayushi Choudhary and Raviraj Zinzuvadia.
Deal value – ~USD 3 billion.
Media coverage – Business Standard
